

UNITED STATES PATENT AND TRADEMARK OFFICE

(12) CERTIFICATE EXTENDING PATENT TERM
UNDER 35 U.S.C. § 156

(68) PATENT NO. : 7,390,791
(45) ISSUED : June 24, 2008
(75) INVENTOR : Mark W. Becker et al.
(73) PATENT OWNER : Gilead Sciences, Inc.
(95) PRODUCT : GENVOYA[®] (cobicistat, emtricitabine,
elvitegravir and tenofovir alafenamide fumarate)

This is to certify that an application under 35 U.S.C. § 156 has been filed in the United States Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 7,390,791 based upon the regulatory review of the product GENVOYA[®] (cobicistat, emtricitabine, elvitegravir and tenofovir alafenamide fumarate) by the Food and Drug Administration. According to United States Patent and Trademark Office records, the original expiration date of the patent as of the date of issuance of this certificate is May 7, 2022. Because it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

(94) 1,076 days

subject to the payment of maintenance fees as provided by law, with all rights pertaining thereto as provided by 35 U.S.C. § 156.

I have caused the seal of the United States Patent and Trademark Office to be affixed this 19th day of August 2020.



Andrei Iancu

Andrei Iancu

Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office